These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19036061)

  • 1. Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
    Tchaikovski SN; van Vlijmen BJ; Cleuren AC; Thomassen MC; Tchaikovski V; Tans G; Rosing J
    J Thromb Haemost; 2009 Feb; 7(2):312-8. PubMed ID: 19036061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
    Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
    J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
    Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J
    Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
    Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
    Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of the APTT- and ETP-based APC sensitivity tests.
    de Visser MC; van Hylckama Vlieg A; Tans G; Rosing J; Dahm AE; Sandset PM; Rosendaal FR; Bertina RM
    J Thromb Haemost; 2005 Jul; 3(7):1488-94. PubMed ID: 15978106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM; Thom JY; Ivey JG; Baker RI
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes.
    Segers O; Simioni P; Tormene D; Castoldi E
    Thromb Haemost; 2014 Mar; 111(3):438-46. PubMed ID: 24226152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
    Tchaikovski SN; Thomassen MC; Costa SD; Bremme K; Rosing J
    Thromb Res; 2014 Nov; 134(5):1032-7. PubMed ID: 25260941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
    Zotz RB; Gerhardt A; Kluft C; Scharf RE
    Thromb Haemost; 2005 Feb; 93(2):306-10. PubMed ID: 15711747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
    Khialani D; Vasan S; Cushman M; Dahm AEA; Sandset PM; Rossouw J; van Hylckama Vlieg A
    J Thromb Haemost; 2021 Jul; 19(7):1729-1737. PubMed ID: 33774921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
    Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
    Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activated protein C resistance and deep venous thrombosis in pregnancy].
    Procházka M; Krcová V; Hrachovec P; Kudela M; Slavík L
    Ceska Gynekol; 2002 Sep; 67(5):251-4. PubMed ID: 12434659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.